Congress, Medicare and industry stakeholders should strike the right balance to cut out fraud in the Medicare Part D drug program while preserving patient access to critical medications, the National Community Pharmacists Association stated in comments submitted in conjunction with a House Energy and Commerce subcommittee hearing Tuesday on the topic.
America’s biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.
On the occasion of the 2015 White House Conference on Aging, which marks the sixth such event since the first in 1961, National Association of Chain Drug Stores president and CEO Steve Anderson joined the dialogue by issuing a statement.
How hard is it to find $24 billion to offset the cost of repealing the medical device tax? As hard as it is “to find a cup of coffee at Starbucks.” That’s according to National Center for Policy Analysis senior fellow John R. Graham, in a Forbes commentary.
The average lost time worker's compensation claim for workers using opioid painkillers can total as much as $117,000 — 900% higher than the cost for workers who do not take opioid painkillers, the National Safety Council says.
Otsuka Pharmaceutical and H. Lundbeck A/S announced Friday that their new medication Rexulti (brexpiprazole) had been approved by the Food and Drug Administration as an adjunctive treatment for major depressive disorder (MDD) and a treament for schizophrenia.
As part of its continued commitment to the practice of pharmacy and the future of the profession, Cardinal Health this year will award a total of more than $1 million to 10 pharmacy schools across the country through its Cardinal Health Pharmacy Scholarship Program.